瑞银发表报告,首次覆盖英硅智能(03696.HK) 予“买入”评级,目标价77港元,相当于预测今年市销率31.3倍,与全球同业一致。该行指出,英硅智能是全球领先的AI驱动药物研发(AIDD)公司,利用其端到端专有的Pharma.AI平台进行药物发现和管线开发,该业务占2025年总收入的87%。该行表示,英硅智能透过整合生成式AI、深度学习和自动化,将目标发现到临床前候选药物(PCC)确认的时间从...
Source Link瑞银发表报告,首次覆盖英硅智能(03696.HK) 予“买入”评级,目标价77港元,相当于预测今年市销率31.3倍,与全球同业一致。该行指出,英硅智能是全球领先的AI驱动药物研发(AIDD)公司,利用其端到端专有的Pharma.AI平台进行药物发现和管线开发,该业务占2025年总收入的87%。该行表示,英硅智能透过整合生成式AI、深度学习和自动化,将目标发现到临床前候选药物(PCC)确认的时间从...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.